Metacrine Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Metacrine Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10998
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Metacrine Inc (Metacrine) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for the treatment of patients with liver and gastrointestinal diseases. The company develops its proprietary portfolio of non-bile acid FXR agonists through its chemistry and biology platform. Its lead program includes, MET409, a next-generation farnesoid X receptor (FXR) agonist intended for the treatment of non-alcoholic steatohepatitis, irritable bowel syndrome with diarrhea and inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. The company also develops a pipeline of drug candidates for the treatment of inflammation and fibrosis. Metacrine is headquartered in San Diego, California, the US.

Metacrine Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Metacrine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Metacrine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Metacrine Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Metacrine Raises USD65 Million in Series C Venture Financing 10
Metacrine Raises USD22 Million in Series B Financing 12
Metacrine Raises USD36 Million in Series A Venture Financing 14
Metacrine Raises USD6.5 Million in Venture Financing 16
Partnerships 17
Metacrine Enters into Agreement with Novo Nordisk 17
Licensing Agreements 18
Metacrine Enters into Licensing Agreement with Salk Institute for Biological Studies 18
Metacrine Enters Into Licensing Agreement with Ronald Evans 19
Metacrine Inc – Key Competitors 20
Metacrine Inc – Key Employees 21
Metacrine Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Corporate Communications 23
Sep 06, 2018: Metacrine names Hubert Chen as Chief Medical Officer and Andrew Guggenhime to the Board of Directors 23
Product News 24
10/10/2017: Metacrine’s FXR Program to be Highlighted in Three Abstracts at The Liver Meeting 2017 in Washington, D.C. 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Metacrine Inc, Pharmaceuticals & Healthcare, Key Facts 2
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Metacrine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Metacrine Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Metacrine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Metacrine Raises USD65 Million in Series C Venture Financing 10
Metacrine Raises USD22 Million in Series B Financing 12
Metacrine Raises USD36 Million in Series A Venture Financing 14
Metacrine Raises USD6.5 Million in Venture Financing 16
Metacrine Enters into Agreement with Novo Nordisk 17
Metacrine Enters into Licensing Agreement with Salk Institute for Biological Studies 18
Metacrine Enters Into Licensing Agreement with Ronald Evans 19
Metacrine Inc, Key Competitors 20
Metacrine Inc, Key Employees 21

List of Figures
Metacrine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Metacrine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Metacrine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Metacrine Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bta Bank Jsc
    Bta Bank Jsc - Strategy, SWOT and Corporate Finance Report Summary Bta Bank Jsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • America Movil, SA DE C.V.:戦略・SWOT・企業財務分析
    America Movil, SA DE C.V. - Strategy, SWOT and Corporate Finance Report Summary America Movil, SA DE C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Aptinyx Inc (APTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Aptinyx Inc. (Aptinyx), formerly Enarex Inc, is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of neurological disorders. The company’s proprietary chemistry platform helps develop a pipeline of small-molecule modulators of N-methyl-D …
  • Medistim ASA (MEDI):企業の財務・戦略的SWOT分析
    Summary MediStim ASA (MediStim) is a medical device company that manufactures and markets medical products for cardiac, vascular and transplant surgeries. The company’s products include MiraQ cardiac, MiraQ vascular, MiraQ ultimate system, imaging probes, flow probes, VeriQ C and VeriQ systems. Its …
  • Trident Systems Incorporated:企業の戦略・SWOT・財務情報
    Trident Systems Incorporated - Strategy, SWOT and Corporate Finance Report Summary Trident Systems Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Kirin Holdings Co Ltd:企業の戦略・SWOT・財務情報
    Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Syndax Pharmaceuticals Inc (SNDX):医療機器:M&Aディール及び事業提携情報
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • Rio Tinto:企業の戦略・SWOT・財務情報
    Rio Tinto - Strategy, SWOT and Corporate Finance Report Summary Rio Tinto - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Sophia Genetics SA:医療機器:M&Aディール及び事業提携情報
    Summary Sophia Genetics SA (Sophia Genetics) is a health tech company that provides technological solutions such as SOPHiA Artificial Intelligence for clinical genomics and next generation sequencing (NGS) data analysis. The company also provides dry lab, bundle solution, and integrated diagnostic s …
  • GlaxoSmithKline Plc (GSK):企業の財務・戦略的SWOT分析
    GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tikcro Technologies Ltd (TIKRF):企業の財務・戦略的SWOT分析
    Summary Tikcro Technologies Ltd (Tikcro) is a biotechnology company that discovers, develops, manufactures and markets antibodies. The company undertakes clinical trials for its pipeline products PD1, PDL1, PDL2, TIGIT and CTLA-4 products, among others. Tikcro products are based on 3D antigens desig …
  • Tianjin Chase Sun Pharmaceutical Co Ltd (300026):製薬・医療:M&Aディール及び事業提携情報
    Summary Tianjin Chase Sun Pharmaceutical Co Ltd (Chase Sun) is a medicine and health industry group. The company research, develops, produces, and markets various pharmaceutical products. It offers products such as Chinese herb preparations, Chinese medicinal granules, synthetic drugs, biotech drugs …
  • Lojas Renner S.A.:企業の戦略・SWOT・財務情報
    Lojas Renner S.A. - Strategy, SWOT and Corporate Finance Report Summary Lojas Renner S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Oil-Dri Corporation of America (ODC):企業の財務・戦略的SWOT分析
    Summary Oil-Dri Corporation of America (Oil-Dri) is a manufacturer and supplier of sorbent products. The company offers granular clay absorbents, universal absorbent products, oil only absorbents, haz mat, socks and boom, spill kits, sweeping compounds, and secondary containment products. Its univer …
  • Prospect Medical Holdings Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Prospect Medical Holdings Inc (PMHI) is a healthcare service provider that offers patient care services. The center offers medical, surgical and psychiatric services, among others. It owns and operates hospitals, clinics and physician networks that offers managed care services for HMO enrole …
  • PKB Privatbank SA:企業の戦略・SWOT・財務情報
    PKB Privatbank SA - Strategy, SWOT and Corporate Finance Report Summary PKB Privatbank SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Tufts University-製薬・医療分野:企業M&A・提携分析
    Summary Tufts University (Tufts) is an educational and research university that offers undergraduate and postgraduate courses in various fields. The university offer courses in anthropology, applied mathematics, architectural engineering, physics, archaeology, Asian American studies, biochemistry, b …
  • Curtiss-Wright Corp (CW):企業の財務・戦略的SWOT分析
    Curtiss-Wright Corp (CW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Wellcome Trust Sanger Institute-製薬・医療分野:企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • Coda Octopus Group Inc:企業の戦略・SWOT・財務情報
    Coda Octopus Group Inc - Strategy, SWOT and Corporate Finance Report Summary Coda Octopus Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆